Medicine and health · Human trial · 23 Oct 2026
mRNA cancer vaccine
- What happened
- Full results from 1,137 patients, presented at the ESMO Congress in Madrid: adding the vaccine to Keytruda cut the risk of recurrence or death by 42%. Healio, 23 Oct 2026
- Why it matters
- Given with the immunotherapy drug Keytruda after surgery for high-risk melanoma, it cut the risk of the cancer coming back, or death, by 42% in a large trial.
- How far from your life
- Real-world testingCould reach you in a few years if the tests go well.



